Biofrontera Inc. Warrants BFRIW

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
37/100
Developing

About Biofrontera Inc. Warrants

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp … Full BFRIW analysis →

Competitive advantage assessment

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.88), suggesting sticky customer base.
  • Operating Leverage in Effect Operating leverage is evident (score 0.73), with margins expanding over time.

Key risks

  • ROIC Below WACC or Peers ROIC at 20.7th percentile suggests inefficient capital deployment.
  • Below-Peer Operating Efficiency Operating margin at 28.7th percentile indicates below-peer efficiency.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
36

Where BFRIW ranks in Drug Manufacturers - Specialty & Generic

Biofrontera Inc. Warrants ranks #55 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 60%. The widest moat in the group is Zoetis Inc. (ZTS) at 85/100.

Moat scores for companies ranked near BFRIW in Drug Manufacturers - Specialty & Generic
# Company Moat score Rating
51 Sonoma Pharmaceuticals, Inc. SNOA 39/100 Developing
52 cbdMD, Inc. YCBD 39/100 Developing
53 BGM Group Ltd. BGM 37/100 Developing
54 Biofrontera Inc. BFRI 37/100 Developing
55 Biofrontera Inc. Warrants BFRIW 37/100 Developing
56 IM Cannabis Corp. IMCC 37/100 Developing
57 Alpha Teknova, Inc. TKNO 36/100 Developing
58 Universe Pharmaceuticals Inc UPC 36/100 Developing
59 Canopy Growth Corporation CGC 35/100 Developing

See every Pharma / Mature Biotech company ranked by moat score →

How BFRIW scores on the Corporate Default defenses

Pricing Power

Score 36 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 25 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 47 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 12 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 47 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 61 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding BFRIW's moat

What is Biofrontera Inc. Warrants's moat score?

Biofrontera Inc. Warrants (BFRIW) scores 37 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #55 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 60%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic. Its strongest defense is Scale & Market Position (61/100) and its weakest is Capital Efficiency (12/100).

How does Biofrontera Inc. Warrants compare with other Drug Manufacturers - Specialty & Generic companies?

Biofrontera Inc. Warrants ranks #55 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are Biofrontera Inc. (BFRI) at 37 just above it and IM Cannabis Corp. (IMCC) at 37 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.

Why is Biofrontera Inc. Warrants scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Biofrontera Inc. Warrants?

The Corporate Default template measures 6 defenses, and BFRIW scores: Pricing Power (36), Cost Advantage (25), Customer Stickiness (47), Capital Efficiency (12), Resilience (47), Scale & Market Position (61). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000